Literature DB >> 15449097

[Transpupillary thermotherapy for subfoveal choroidal neovascularization. A 9-month follow-up].

M Feucht1, B Fuisting, G Richard.   

Abstract

PURPOSE: The purpose of this study was to evaluate the efficiency, stability, and safety of transpupillary thermotherapy as a treatment of subfoveal occult choroidal neovascularizations (CNV) in age-related macular degeneration.
METHODS: Transpupillary thermotherapy (TTT) was performed in 40 patients with uni- or bilateral predominantly occult CNV. Laser light derived from an infrared diode laser at 810 nm was used to apply spots for a duration of 60 s. A complete ophthalmic examination was performed prior to and 9 months after the treatment.
RESULTS: After 9 months, visual acuity remained stable in 65% (+/-2 lines). In 35% of the patients TTT could not prevent further visual loss. Retinal leakage, assessed by fluorescein angiography, stabilized in 67.5% of the treated patients.
CONCLUSIONS: The present data show stabilization of visual acuity in 65% after TTT. Compared to the natural course of occult and mixed subfoveal CNV, these data give some evidence for patient benefit after TTT.

Entities:  

Mesh:

Year:  2004        PMID: 15449097     DOI: 10.1007/s00347-004-1114-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  22 in total

Review 1.  Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins.

Authors:  M A Mainster; E Reichel
Journal:  Ophthalmic Surg Lasers       Date:  2000 Sep-Oct

2.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

3.  Porphyrin photosensitivity in cell lines expressing a heat-resistant phenotype.

Authors:  C J Gomer; N Rucker; S Wong
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

4.  Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation.

Authors:  R S Newsom; J C McAlister; M Saeed; J D McHugh
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

Review 5.  Failla memorial lecture. The search for critical cellular targets damaged by heat.

Authors:  W C Dewey
Journal:  Radiat Res       Date:  1989-11       Impact factor: 2.841

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration.

Authors:  E Reichel; A M Berrocal; M Ip; A J Kroll; V Desai; J S Duker; C A Puliafito
Journal:  Ophthalmology       Date:  1999-10       Impact factor: 12.079

8.  Occult choroidal neovascularization in age-related macular degeneration. A natural history study.

Authors:  T S Stevens; N M Bressler; M G Maguire; S B Bressler; S L Fine; J Alexander; D A Phillips; R R Margherio; P L Murphy; A P Schachat
Journal:  Arch Ophthalmol       Date:  1997-03

9.  Photocoagulation of choroidal neovascular membranes with a diode laser.

Authors:  M W Ulbig; D A McHugh; A M Hamilton
Journal:  Br J Ophthalmol       Date:  1993-04       Impact factor: 4.638

10.  Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-04
View more
  1 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.